Table 1. Characteristics of the selected RCTs.
| References Characteristics | Lee et al 2012 | Kim et al 2012 | Zhu et al 2012 | |||
| CT | CRT | CT | CRT | CT | CRT | |
| Total number | 228 | 230 | 44 | 46 | 165 | 186 |
| Age year(range) | 56(22–77) | 56(28–76) | NR | NR | 59(42–75) | 56(38–73) |
| Sex No. (%) | ||||||
| Male | 153(67.1) | 143(62.2) | 25(56.8) | 34(73.9) | 126(76.4) | 135(72.9) |
| Female | 75(32.9) | 87(37.8) | 19(43.2) | 12(26.1) | 39(23.6) | 51(27.1) |
| ECOG PS No. (%) | ||||||
| 0 | 96(42.1) | 99(43.0) | 27(61.4) | 35(76.1) | NR | NR |
| 1 | 132(57.9) | 131(57.0) | 17(38.6) | 11(23.9) | NR | NR |
| Primary tumor site No.(%) | ||||||
| Proximal | 9(3.9) | 13(5.7) | 2(4.5) | 3(6.5) | 15(9.1) | 30(16.1) |
| Body | 112(49.1) | 107(46.5) | 19(43.2) | 26(56.5) | 33(20) | 21(11.3) |
| Antrum | 87(38.2) | 90(39.1) | 18(40.9) | 14(30.5) | 117(70.9) | 135(72.6) |
| Multiple/diffuse | 20(8.8) | 20(8.7) | 5(11.4) | 3(6.5) | 0 | 0 |
| Lauren classification No. (%) | ||||||
| Intestinal | 88(38.6) | 75(32.6) | 15(34.1) | 16(34.8) | NR | NR |
| Diffuse | 130(57.0) | 144(62.6) | 24(54.5) | 26(56.5) | NR | NR |
| Mixed | 6(2.6) | 8(3.5) | 3(6.8) | 2(4.3) | NR | NR |
| Not specified | 4(1.8) | 3(1.3) | 2(4.5) | 2(4.3) | NR | NR |
| Tumor stage No. (%) | ||||||
| IB | 50(21.9) | 49(21.3) | 0 | 0 | 15(9.1) | 20(10.8) |
| II | 86(37.7) | 84(36.5) | 0 | 0 | 30(18.2) | 36(19.4) |
| III | 65(28.6) | 71(30.8) | 31 (75) | 34 (73.9) | 96(58.2) | 103(55.4) |
| IV(M0) | 27(11.8) | 26(11.3) | 11(25) | 12(26.1) | 24(14.5) | 27(14.5) |
| Treatment regimens | XP# | XP/XRT/XP* | FL<$>\vskip -1.5\scale 70%\raster="rg1"<$> | FL/RT§ | FL<$>\vskip -1.5\scale 70%\raster="rg1"<$> | FL/IMRT¶ |
| Endpoints | 3-ys DFS: 74.2% vs 78.2%, p = 0.0862 | 5-ys DFS: 50.0% vs 60.9%, p = 0.246 | 5-ys RFS: 35.8% vs 45.2%, p = 0.029 | |||
| OS not reached when data analyzed | 5-ys OS: 54.6% vs 65.2%, p = 0.67 | 5-ys OS: 41.8% vs 48.4%, p = 0.122 | ||||
| Follow-up month Median(range) | 53.2(36.9–77.3) | 86.7(60.3–116.5) | 42.5 | |||
| Jadad scale score | 3 | 3 | 3 | |||
CT: chemotherapy, CRT: chemoradiotherapy, NR: not reported, 3-ys DFS: 3-year disease-free survival, 5-ys DFS: 5-year disease-free survival, 5-ys RFS: 5-year recurrence-free survival, 5-ys OS: 5-year overall survival.
XP regimen: capecitabine 1000 mg/m2 twice daily on days 1 to 14; cisplatin 60 mg/m2 on day 1 every 3 weeks, totally 6 cycles.
XP/XRT/XP: Two cycles of XP, then XRT (45 Gy of radiation at 1.8 Gy per day, 5 days per week, for 5 weeks with continuous capecitabine 825 mg/m2 twice daily during radiotherapy), followed by two cycles of XP.
FL regimen: 5-fu 425 mg/m2, leucovorin 20 mg/m2, for 5 days with a 4-week interval, totally 5 cycles.
FL/RT: 1 cycle of FL, then RT(45 Gy of radiation at 1.8 Gy per day, 5 days per week, for 5 weeks with 2 cycles of FL), followed by two cycles of FL.
FL/IMRT: 1 cycle of FL, then IMRT (45 Gy of radiation at 1.8 Gy per day, 5 days per week, for 5 weeks with 2 cycles of FL), followed by two cycles of FL.